Germany’s Complement Bets On Gene Therapy For Geographic Atrophy
As Series A Raises €72m
US approval of Apellis's Syfovre has validated the complement approach for treating the advanced stage of age-related macular degeneration but a Munich-headquartered start-up believes its gene therapy will be a more potent and less burdensome alternative.
